Table of Contents
ISRN Pharmacology
Volume 2013, Article ID 352865, 5 pages
http://dx.doi.org/10.1155/2013/352865
Review Article

The Pharmacological Options in the Treatment of Eating Disorders

1Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
2Department of Pharmacy, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno, Italy

Received 10 May 2013; Accepted 18 June 2013

Academic Editors: A. Fernandez-Guasti and J.-A. Mico

Copyright © 2013 W. Milano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Psychiatric Association (APA), Diagnostic and Statistic Manual of Mental Disorders, APA, Waschington, DC, USA, 4th edition, 2000.
  2. A. Capasso, C. Petrella, and W. Milano, “Recent clinical aspects of eating disorders,” Reviews on Recent Clinical Trials, vol. 4, no. 1, pp. 63–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. I. Hudson, E. Hiripi, H. G. Pope Jr., and R. C. Kessler, “The prevalence and correlates of eating disorders in the national comorbidity survey replication,” Biological Psychiatry, vol. 61, no. 3, pp. 348–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Treasure, A. M. Claudino, and N. Zucker, “Eating disorders,” The Lancet, vol. 375, no. 9714, pp. 583–593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. National Institute for Clinic Excellence, “Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimis nervosa and related disorders,” London, UK, Clinical guideline Number 9. 2004.
  6. M. Aigner, J. Treasure, W. Kaye, and S. Kasper, “World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders,” World Journal of Biological Psychiatry, vol. 12, no. 6, pp. 400–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. American Psychiatric Association (APA), “Practice guidelines for the treatment of patients with eating disorders,” in Practice Guidelines for the Treatment of Psychiatric Disorders, 3th edition, 2006. View at Google Scholar
  8. P. J. Hay and A. M. Claudino, “Clinical psychopharmacology of eating disorder: a research update,” International Journal of Neuropsychopharmacology, vol. 6, pp. 1–14, 2011. View at Google Scholar
  9. R. F. McKnight and R. J. Park, “Atypical antipsychotics and anorexia nervosa: a review,” European Eating Disorders Review, vol. 18, no. 1, pp. 10–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. S. Powers and C. Santana, “Available pharmacological treatments for anorexia nervosa,” Expert Opinion on Pharmacotherapy, vol. 5, no. 11, pp. 2287–2292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Vandereycken, “Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride,” British Journal of Psychiatry, vol. 144, no. 3, pp. 288–292, 1984. View at Google Scholar · View at Scopus
  12. M. F. Flament, H. Bissada, and W. Spettigue, “Evidence-based pharmacotherapy of eating disorders,” International Journal of Neuropsychopharmacology, vol. 15, no. 2, pp. 189–207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Mondraty, C. Laird Birmingham, S. Touyz, V. Sundakov, L. Chapman, and P. Beumont, “Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa,” Australasian Psychiatry, vol. 13, no. 1, pp. 72–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Brambilla, C. S. Garcia, S. Fassino et al., “Olanzapine therapy in anorexia nervosa: psychobiological effects,” International Clinical Psychopharmacology, vol. 22, no. 4, pp. 197–204, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Bissada, G. A. Tasca, A. M. Barber, and J. Bradwejn, “Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial,” American Journal of Psychiatry, vol. 165, no. 10, pp. 1281–1288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. S. Powers and H. Bruty, “Pharmacotherapy for eating disorders and obesity,” Child and Adolescent Psychiatric Clinics of North America, vol. 18, no. 1, pp. 175–187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. L. McElroy and A. I. Guerdjikova, “Current pharmacotherapy options for bulimia nervosa and binge eating disorder,” Expert Opinion on Pharmacotherapy, vol. 13, pp. 2015–2026, 2012. View at Google Scholar
  18. D. Mischoulon, K. T. Eddy, A. Keshaviah et al., “Depression and eating disorders: treatment and course,” Journal of Affective Disorders, vol. 130, no. 3, pp. 470–477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Brambilla, “Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment,” CNS Drugs, vol. 15, no. 2, pp. 119–136, 2001. View at Google Scholar · View at Scopus
  20. K. A. Halmi, E. Eckert, T. J. LaDu, and J. Cohen, “Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline,” Archives of General Psychiatry, vol. 43, no. 2, pp. 177–181, 1986. View at Google Scholar · View at Scopus
  21. T. Walsch and A. S. Kaplan, “Fluoxetina after weight restoration in anorexia nervosa,” Journal of the American Medical Association, vol. 295, pp. 2605–2612, 2006. View at Google Scholar
  22. W. H. Kaye, “Neurobiology of anorexia nervosa purdue ingestive behavior research center symposium influences on eating and body weight over the lifespan: children and adolescents,” Physiology & Behavior, vol. 94, pp. 121–135, 2008. View at Google Scholar
  23. A. Capasso, C. Petrella, and W. Milano, “Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders,” Current Clinical Pharmacology, vol. 4, no. 1, pp. 78–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Bacaltchuk and P. Hay, “Antidepressants versus placebo for people with bulimia nervosa,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003391, 2001. View at Google Scholar · View at Scopus
  25. W. Milano, C. Petrella, C. Sabatino, and A. Capasso, “Treatment of bulimia nervosa with sertraline: a randomized controlled trial,” Advances in Therapy, vol. 21, no. 4, pp. 232–237, 2004. View at Google Scholar · View at Scopus
  26. W. Milano, C. Siano, C. Putrella, and A. Capasso, “Treatment of Bulimia nervosa with fluvoxamine: a randomized controlled trial,” Advances in Therapy, vol. 22, no. 3, pp. 278–283, 2005. View at Google Scholar · View at Scopus
  27. V. Martiadis, E. Castaldo, P. Monteleone, and M. Maj, “The role of psychopharmacotherapy in the treatment of eating disorders,” Clinical Neuropsychiatry, vol. 4, no. 2, pp. 51–60, 2007. View at Google Scholar · View at Scopus
  28. S. J. Romano, K. A. Halmi, N. P. Sarkar, S. C. Koke, and J. S. Lee, “A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment,” American Journal of Psychiatry, vol. 159, no. 1, pp. 96–102, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. S. C. Stefano, J. Bacaltchuk, S. L. Blay, and J. C. Appolinário, “Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis,” Eating Behaviors, vol. 9, no. 2, pp. 129–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Reas and C. M. Grilo, “Review and meta-analysis of pharmacotherapy for binge-eating disorder,” Obesity, vol. 16, no. 9, pp. 2024–2038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. I. Guerdjikova, S. L. McElroy, E. L. Winstanley et al., “Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial,” International Journal of Eating Disorders, vol. 45, no. 2, pp. 281–289, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Appolinario, J. Bacaltchuk, R. Sichieri et al., “A randomized, double-blind, placebo-controlled study of sibutramina in the treatment of binge eating disorder,” Archives of General Psychiatry, vol. 60, no. 11, pp. 1109–1116, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Milano, C. Petrella, A. Casella, A. Capasso, S. Carrino, and L. Milano, “Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study,” Advances in Therapy, vol. 22, no. 1, pp. 25–31, 2005. View at Google Scholar · View at Scopus
  34. R. L. Horne, J. M. Ferguson, H. G. Pole Jr. et al., “Treatment of bulimia with bupropion: a multicenter controlled trial,” Journal of Clinical Psychiatry, vol. 49, no. 7, pp. 262–266, 1988. View at Google Scholar · View at Scopus
  35. O. Gao and T. L. Horvast, “Neuronal control of henergy homeostasis,” FEBS Letters, vol. 582, pp. 132–141, 2008. View at Google Scholar
  36. B. Meister, “Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight,” Physiology & Behavior, vol. 92, no. 1-2, pp. 263–271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. S. L. McElroy, A. I. Guerdjikova, B. Martens, P. E. Keck Jr., H. G. Pope, and J. I. Hudson, “Role of antiepileptic drugs in the management of eating disorders,” CNS Drugs, vol. 23, no. 2, pp. 139–156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. D. W. Hedges, F. W. Reimherr, S. P. Hoopes et al., “Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial—part 2: improvement in psychiatric measures,” Journal of Clinical Psychiatry, vol. 64, no. 12, pp. 1449–1454, 2003. View at Google Scholar · View at Scopus
  39. S. P. Hoopes, F. W. Reimherr, D. W. Hedges et al., “Treatment of bulimia nervosa with topiramato in a randomized, double-blind, placebo controlled trial—part 1: improvement in psychiatric measures,” Journal of Clinical Psychiatry, vol. 64, no. 11, pp. 1335–1341, 2003. View at Google Scholar · View at Scopus
  40. C. Nickel, K. Tritt, M. Muehlbacher et al., “Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial,” International Journal of Eating Disorders, vol. 38, no. 4, pp. 295–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. L. McElroy, J. I. Hudson, J. A. Capece, K. Beyers, A. C. Fisher, and N. R. Rosenthal, “Topiramato for treatment of binge eating disorder associated ad obesity: a placebo,” Biological Psychiatry, vol. 61, no. 9, pp. 1039–1048, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Ricca, G. Castellini, C. Lo Sauro, C. M. Rotella, and C. Faravelli, “Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study,” Psychiatry, vol. 6, no. 11, pp. 23–28, 2009. View at Google Scholar · View at Scopus
  43. A. Golay, A. Laurent-Jaccard, F. Habicht et al., “Effect of orlistat in obese patients with binge eating disorder,” Obesity Research, vol. 13, no. 10, pp. 1701–1708, 2005. View at Google Scholar · View at Scopus
  44. S. L. McElroy, A. Guerdjikova, R. Kotwal et al., “Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 68, no. 3, pp. 390–398, 2007. View at Google Scholar · View at Scopus
  45. M. Cuzzolaro, “Il trattamento dei disturbi del comportamento alimentare,” Noos, vol. 1, pp. 49–66, 2003. View at Google Scholar
  46. L. R. Levine, H. G. Pope Jr., G. G. Enas et al., “Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo- controlled, double-blind trial,” Archives of General Psychiatry, vol. 49, no. 2, pp. 139–147, 1992. View at Google Scholar · View at Scopus